Anzeige
Mehr »
Freitag, 07.08.2026 - Börsentäglich über 12.000 News
Schwere Seltene Erden: Entsteht hier die nächste Milliardenstory?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
07.08.26 | 16:13
30,130 Euro
+1,65 % +0,490
Branche
Chemie
Aktienmarkt
Japan 225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
29,95030,31017:15
29,94030,24017:13

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
DoTakeda approval ushers in new wave of sleep drugs23
DoTakeda gains FDA nod for first-in-class narcolepsy treatment Orzeyful3
DoTakeda Achieves Major Milestone With Holistic Narcolepsy Drug Approval3
DoTakeda nets first-in-class advantage on narcolepsy drug's FDA go-ahead3
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
DoTakeda's first-in-class narcolepsy drug claims FDA approval5
DoTAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer-
DoTAKEDA PHARMACEUTICAL COMPANY LIMITED: GENERAL ANNOUNCEMENT::U.S. FDA APPROVES TAKEDA ORZEYFUL (OVEPOREXTON)6
30.07.Keros to receive $20 million milestone from Takeda partnership4
30.07.Keros Therapeutics, Inc.: Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda188LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics...
► Artikel lesen
30.07.Takeda scraps another phase 2 celiac disease therapy, narrowing pipeline to one25
30.07.Takeda Pharmaceutical Q1 Net Profit Slips From Higher Costs; Reaffirms FY26 Outlook367TOKYO (dpa-AFX) - On Thursday, Takeda Pharmaceutical Company Ltd. (TAK) reported decline in first quarter profit, dented by higher costs, despite higher revenues. Further, the company reiterated...
► Artikel lesen
30.07.Takeda Q1 FY2026 slides: three launches ahead as revenue dips17
30.07.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer4
30.07.TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::FIRST QUARTER RESULTS12
30.07.Takeda Pharmaceutical reports Q1 results20
23.07.Takeda gets first OK for orexin narcolepsy drug, in China11
22.07.Takeda's zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies6
20.07.Novartis and Takeda drugs gain rare blood cancer routine use on NHS22
17.07.Takeda reports zasocitinib psoriasis trial results at AAD meeting15
16.07.Racing Takeda, InnoCare reports TYK2 inhibitor win in phase 2 vitiligo trial14
Weiter >>
172 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1